HRC 101

Drug Profile

HRC 101

Alternative Names: HML 109

Latest Information Update: 13 Sep 2010

Price : $50

At a glance

  • Originator Hemosol Corp
  • Developer Hemosol BioPharma
  • Class
  • Mechanism of Action Oxygen carriers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Anaemia

Most Recent Events

  • 05 Sep 2007 Hemosol is seeking funding, co-development and/or out-licensing opportunities for HRC 101 (http://www.hemosol.com/)
  • 19 Jul 2007 Hemosol Corp. is now a wholly-owned subsidiary of Catalyst Fund Ltd. Partnership II; the pharmaceutical business will be known as Hemosol BioPharma Inc.
  • 26 Aug 2005 HRC 101 is still available for licensing (http://www.hemosol.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top